Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Australia's HealthLinx Collaborates with Bruker Daltonics on Mass Spectrometry-Based Disease-Specific IVD Assays

09 Jun 2005 - HealthLinx Pty. Limited announced that it has entered into a collaboration with Bruker Daltonics Inc. The collaboration focuses on technology transfer and cooperation between the two firms to develop disease-specific assays for use in in-vitro diagnostic (IVD) research and clinical trials using Bruker Daltonics' CLINPROT(TM) platform technology for clinical proteomics.
 
The collaboration involves the on-going discovery of new biomarkers for predictive diagnostic applications using Bruker Daltonics' autoflex(TM) MALDI-TOF mass spectrometer in combination with proprietary CLINPROT magnetic bead sample preparation, and ClinProTools(TM) software for advanced visualization and bioinformatics. HealthLinx will apply this technology platform to develop and commercialize biomarker applications in women's health for both research and clinical diagnostics. It is envisaged that, following validation, Australian government Therapeutic Goods Administration (TGA) registration of the CLINPROT platform as a diagnostic pathology device will be sought. TGA registration has effect in both Australia and New Zealand, and is valuable in Singapore and Europe.